- Home
- NVCT vs CGBD Comparison
NVCT vs CGBD Comparison
Compare NVCT & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | CGBD |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.2M | 751.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVCT | CGBD |
|---|---|---|
| Price | $19.08 | $10.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $12.92 |
| AVG Volume (30 Days) | ★ 589.5K | 570.7K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | N/A | $1.80 |
| P/E Ratio | ★ N/A | $10.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $10.25 |
| 52 Week High | $29.28 | $14.32 |
Technical Indicators
Market Signals| Indicator | NVCT | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 44.51 |
| Support Level | $18.02 | N/A |
| Resistance Level | $29.28 | $11.12 |
| Average True Range (ATR) | 1.26 | 0.26 |
| MACD | -0.50 | 0.00 |
| Stochastic Oscillator | 38.24 | 23.49 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.